• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (27)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Troglitazone represents a new molecular entity class of insulin-sensitizing drugs, the thiazolidinediones, and is approved for the treatment of type 2 diabetes as monotherapy or in combination with other antidiabetic drugs.¹ Thiazolidinediones, including troglitazone, have recently been shown to have antiproliferative² and anti-inflammatory³ effects in human cells. Because psoriasis is a proliferative, inflammatory disease of the skin, we hypothesized that in diabetic patients with poor glycemic control with coexisting psoriasis, oral administration of troglitazone would not only improve their glycemic control, but also produce significant resolution of their psoriasis.

Patients and Methods

An open-label study was conducted in 3 diabetic patients with poor glycemic control and concomitant psoriasis. All 3 patients underwent trials of high-potency glucocorticoid therapy (0.1% triamcinolone acetonide), which were discontinued because of worsening of their glycemic control, because they became recalcitrant to the therapy, or both. Troglitazone was given at a dosage of 400 to 600 mg/d until acceptable glycemic . . . [Full Text of this Article]

Comment


CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy and Safety of Combination Acitretin and Pioglitazone Therapy in Patients With Moderate to Severe Chronic Plaque-Type Psoriasis: A Randomized, Double-blind, Placebo-Controlled Clinical Trial
Mittal et al.
Arch Dermatol 2009;145:387-393.
ABSTRACT | FULL TEXT  

BP-1107 [{2-[4-(2,4-Dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: A Novel Synthetic Thiazolidinedione That Inhibits Epidermal Hyperplasia in Psoriatic Skin-Severe-Combined Immunodeficient Mouse Transplants after Topical Application
Bhagavathula et al.
J. Pharmacol. Exp. Ther. 2005;315:996-1004.
ABSTRACT | FULL TEXT  

Peroxisome Proliferator-Activated Receptor-{gamma}-Deficient Heterozygous Mice Develop an Exacerbated Neural Antigen-Induced Th1 Response and Experimental Allergic Encephalomyelitis
Bright et al.
J. Immunol. 2003;171:5743-5750.
ABSTRACT | FULL TEXT  

Troglitazone Improves Psoriasis and Normalizes Models of Proliferative Skin Disease: Ligands for Peroxisome Proliferator-Activated Receptor-{gamma} Inhibit Keratinocyte Proliferation
Ellis et al.
Arch Dermatol 2000;136:609-616.
ABSTRACT | FULL TEXT